Alcon Pays $550M for Neurotech, Adding Only FDA-Approved MacTel Therapy
ALC is trading near its 52-week low of $61.835 (9.4% above the low).
Summary
Alcon is buying private biotech Neurotech Pharmaceuticals for $550 million upfront, plus undisclosed commercial milestone payments. The prize is ENCELTO, an implanted cell therapy that is the only FDA-approved treatment for MacTel Type 2, a rare retinal disease with roughly 25,000 diagnosed US patients and 2,000-3,000 new cases a year. The deal slots into Alcon's surgical retina franchise and gives it a first-mover product in an indication that previously had no approved options. Management guides the deal to be modestly accretive to net sales growth and slightly dilutive to core diluted EPS in 2027, turning accretive after that. This follows the August Q2 print where sales rose 8% to $2.8 billion and full-year margin and EPS guidance was raised, and the October OTC approval for Brytly eye drops — Alcon is stacking incremental growth drivers onto a strong base.
At the time of this announcement, ALC was trading at $67.65 on NYSE in the Life Sciences sector, with a market capitalization of approximately $33.9B. The 52-week trading range was $61.84 to $87.64. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.